Developer docs
API playgroundTry for free, no card

Search company profiles

LEXEO Therapeutics

Full company profile

uuid00003cz

Namestring
LEXEO Therapeutics
Legal namestring
Lexeo Therapeutics, Inc.
Websiteurl
lexeotx.com
Company typeenum
Public
Founded yearint
2020
Descriptiontext

LEXEO Therapeutics is a clinical-stage genetic medicine company developing AAV-based gene therapies for genetically defined cardiovascular and central nervous system diseases, founded in 2020 and headquartered in New York (NASDAQ: LXEO). The pipeline is anchored by a proprietary AAVrh.10 capsid delivery platform paired with a scalable Sf9-baculovirus suspension manufacturing process (scaled from 10L to 200L), and is organized into two therapeutic pillars. The cardiac pillar includes lead asset LX2006 (AAVrh.10hFXN for Friedreich ataxia cardiomyopathy, Phase 1/2 with pivotal SUNRISE-FA 2 protocol finalized), LX2020 (AAVrh.10hPKP2 for PKP2-associated arrhythmogenic cardiomyopathy, Phase 1/2), and preclinical LX2021 (Cx43 for desmoplakin cardiomyopathy) and LX2022 (TNNI3 for hypertrophic cardiomyopathy). The CNS pillar comprises LX1001 (APOE2 in Phase 1/2 for APOE4 homozygous Alzheimer's), and preclinical LX1020 and LX1021 (APOE2 with APOE4 miRNA suppression and Christchurch-modified APOE2, respectively). The lead asset has accumulated FDA Breakthrough Therapy, RMAT, Fast Track, Rare Pediatric Disease, and Orphan Drug designations plus EU Orphan Medicinal Product status; LX2020 holds Orphan Drug and Fast Track; LX1001 holds Fast Track.

The company generates no product revenue and is funded primarily through equity financings and strategic partner capital. Cumulative disclosed funding exceeds $548M since 2021, including a $100M Series B (2021), a Sarepta Therapeutics strategic investment (2023), a $95M PIPE (March 2024), an $80M PIPE (May 2025), a $40M round (June 2025), and a $153.8M public offering with concurrent private placement (October 2025), with stated runway into 2028. Strategic research collaborations include Johnson & Johnson/Abiomed for Impella-based cardiac AAV delivery (January 2026), BioAgilytix Labs for the FDA Breakthrough Device-designated anti-AAV antibody assay, and the co-founded Myoventive, Inc. (June 2025) for next-generation cardiac precision medicines. The company sponsors the CLARITY-FA natural history study to serve as an external control arm for SUNRISE-FA 2.

LEXEO is led by CEO R. Nolan Townsend (former President of Pfizer Rare Disease), with founder Ronald Crystal, MD (Weill Cornell Department of Genetic Medicine) as Chief Scientific Adviser, and Chairman Steven Altschuler, MD (former Spark Therapeutics board chair). Future revenue, when it materializes, will follow a one-time specialty rare-disease pricing model per patient, distributed through specialty rare-disease channels and academic medical centers; no commercial product is approved today.

Short descriptiontext

LEXEO Therapeutics is a clinical-stage gene therapy company developing AAVrh.10-based treatments for genetically defined cardiovascular and CNS diseases, including Friedreich ataxia cardiomyopathy, arrhythmogenic and other cardiomyopathies, and APOE4-associated Alzheimer's disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
gene therapy development, AAV vector therapeutics, cardiovascular gene therapy, rare disease treatments, CNS gene therapy
Industry5 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Genetic medicines / AAV gene therapy biopharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pre-revenue clinical-stage development
TypeOne Time License
Description

LEXEO is a clinical-stage genetic medicine company with no approved products and no product revenue; future revenue will derive from commercialization of gene therapy candidates for cardiovascular and CNS indications (one-time treatment per patient model, consistent with specialty rare-disease therapeutics).

lexeotx.com
2Strategic equity / collaboration income (capital)
TypeLicensing Royalties
Description

Capital raised from strategic partners (e.g., Sarepta Therapeutics strategic investment, Johnson & Johnson research collaboration) and equity financings from institutional investors; not a recurring operating revenue stream.

lexeotx.com
Cost components1 value
Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1LEXEO
Description

Corporate trade name used interchangeably with Lexeo Therapeutics across investor relations, clinical trials website, and corporate communications.

lexeotx.com
Core offering1 text field

LEXEO Therapeutics is a clinical-stage genetic medicine company that develops adeno-associated virus (AAV)-based gene therapies to treat genetically defined cardiovascular and central nervous system diseases. Its pipeline includes lead candidate LX2006 for Friedreich ataxia cardiomyopathy (pivotal SUNRISE-FA 2 trial initiating Q2 2026), plus LX2020 (PKP2-ACM), LX2021 (DSP cardiomyopathy), LX2022 (TNNI3 HCM) in cardiology, and LX1001, LX1020, LX1021 targeting APOE4-associated Alzheimer's disease. All candidates are built on a proprietary AAVrh.10 capsid platform with an optimized Sf9-baculovirus suspension manufacturing process.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

LEXEO Therapeutics is a clinical-stage genetic medicine company with a portfolio of AAV-based gene therapy candidates organized around two main program pillars: (1) Cardiac programs — LX2006 (Friedreich Ataxia cardiomyopathy, lead asset in Phase 1/2 with SUNRISE-FA 2 pivotal trial initiating), LX2020 (PKP2-ACM, Phase 1/2), LX2021 (DSP cardiomyopathy, preclinical), and LX2022 (TNNI3 HCM, preclinical) — and (2) CNS programs targeting APOE4-associated Alzheimer's disease — LX1001 (Phase 1/2), LX1020, and LX1021. All candidates are built on the company's proprietary AAVrh10 vector delivery platform supported by an Sf9-baculovirus manufacturing process. LEXEO also conducts the CLARITY-FA natural history study (to serve as external control for LX2006) and the HEROIC-PKP2 clinical trial for LX2020. The company retains exclusive worldwide development and commercialization rights to all candidates and pursues both internal development and research collaborations (e.g., Johnson & Johnson for cardiac delivery, BioAgilytix for anti-AAV antibody assay).

Product and service7 records
1LX2006
CategoryClinical-stage gene therapy candidate (cardiac)
Description

AAV-based gene therapy candidate (AAVrh.10hFXN) designed to deliver a functional frataxin (FXN) gene to myocardial cells to treat Friedreich ataxia (FA) cardiomyopathy, restoring mitochondrial function and energy production in cardiac myocytes. Lead clinical-stage asset with FDA Breakthrough Therapy, RMAT, Fast Track, Rare Pediatric Disease, and Orphan Drug designations plus EU Orphan Medicinal Product designation.

2LX2020
CategoryClinical-stage gene therapy candidate (cardiac)
Description

AAV-based gene therapy (AAVrh.10hPKP2) designed to intravenously deliver a fully functional PKP2 gene to cardiac muscle for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Granted FDA Orphan Drug and Fast Track designations; evaluated in the HEROIC-PKP2 Phase I/II trial.

3LX2021
CategoryPreclinical gene therapy candidate (cardiac)
Description

Gene therapy candidate designed to deliver functional connexin 43 (Cx43) protein for a group of inherited cardiac muscle disorders including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. Initially targeting Desmoplakin (DSP) cardiomyopathy.

4LX2022
CategoryPreclinical gene therapy candidate (cardiac)
Description

Gene therapy candidate designed to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy (HCM) due to mutations in the TNNI3 gene, accounting for approximately 5% of all HCM cases.

5LX1001
CategoryClinical-stage gene therapy candidate (CNS)
Description

AAV-based gene therapy candidate designed to express the protective APOE2 protein in the CNS of APOE4 homozygous patients to halt or slow the progression of Alzheimer's disease. Granted FDA Fast Track designation; evaluated in the LEAD Phase 1/2 clinical trial.

6LX1020
CategoryPreclinical gene therapy candidate (CNS)
Description

Gene therapy candidate designed to express the protective APOE2 protein in the CNS of APOE4 homozygous patients while concurrently delivering miRNA to suppress APOE4 expression, achieving conversion to APOE4/E2 heterozygous profile.

7LX1021
CategoryPreclinical gene therapy candidate (CNS)
Description

Gene therapy candidate designed to express the Christchurch-modified APOE2 protein in the CNS of APOE4 homozygous patients; the Christchurch mutation has been observed to protect patients against Alzheimer's disease even in the presence of significant amyloid pathology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors32 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LEXEO Therapeutics

Genetic medicines / AAV gene therapy biopharmaceuticalslexeotx.com

LEXEO Therapeutics is a clinical-stage gene therapy company developing AAVrh.10-based treatments for genetically defined cardiovascular and CNS diseases, including Friedreich ataxia cardiomyopathy, arrhythmogenic and other cardiomyopathies, and APOE4-associated Alzheimer's disease.

What LEXEO Therapeutics does

LEXEO Therapeutics is a clinical-stage genetic medicine company developing AAV-based gene therapies for genetically defined cardiovascular and central nervous system diseases, founded in 2020 and headquartered in New York (NASDAQ: LXEO). The pipeline is anchored by a proprietary AAVrh.10 capsid delivery platform paired with a scalable Sf9-baculovirus suspension manufacturing process (scaled from 10L to 200L), and is organized into two therapeutic pillars. The cardiac pillar includes lead asset LX2006 (AAVrh.10hFXN for Friedreich ataxia cardiomyopathy, Phase 1/2 with pivotal SUNRISE-FA 2 protocol finalized), LX2020 (AAVrh.10hPKP2 for PKP2-associated arrhythmogenic cardiomyopathy, Phase 1/2), and preclinical LX2021 (Cx43 for desmoplakin cardiomyopathy) and LX2022 (TNNI3 for hypertrophic cardiomyopathy). The CNS pillar comprises LX1001 (APOE2 in Phase 1/2 for APOE4 homozygous Alzheimer's), and preclinical LX1020 and LX1021 (APOE2 with APOE4 miRNA suppression and Christchurch-modified APOE2, respectively). The lead asset has accumulated FDA Breakthrough Therapy, RMAT, Fast Track, Rare Pediatric Disease, and Orphan Drug designations plus EU Orphan Medicinal Product status; LX2020 holds Orphan Drug and Fast Track; LX1001 holds Fast Track.

The company generates no product revenue and is funded primarily through equity financings and strategic partner capital. Cumulative disclosed funding exceeds $548M since 2021, including a $100M Series B (2021), a Sarepta Therapeutics strategic investment (2023), a $95M PIPE (March 2024), an $80M PIPE (May 2025), a $40M round (June 2025), and a $153.8M public offering with concurrent private placement (October 2025), with stated runway into 2028. Strategic research collaborations include Johnson & Johnson/Abiomed for Impella-based cardiac AAV delivery (January 2026), BioAgilytix Labs for the FDA Breakthrough Device-designated anti-AAV antibody assay, and the co-founded Myoventive, Inc. (June 2025) for next-generation cardiac precision medicines. The company sponsors the CLARITY-FA natural history study to serve as an external control arm for SUNRISE-FA 2.

LEXEO is led by CEO R. Nolan Townsend (former President of Pfizer Rare Disease), with founder Ronald Crystal, MD (Weill Cornell Department of Genetic Medicine) as Chief Scientific Adviser, and Chairman Steven Altschuler, MD (former Spark Therapeutics board chair). Future revenue, when it materializes, will follow a one-time specialty rare-disease pricing model per patient, distributed through specialty rare-disease channels and academic medical centers; no commercial product is approved today.

LEXEO Therapeutics firmographics

Firmographics
Name
LEXEO Therapeutics
Legal name
Lexeo Therapeutics, Inc.
Website
https://lexeotx.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
101–250 employees
Short description
LEXEO Therapeutics is a clinical-stage gene therapy company developing AAVrh.10-based treatments for genetically defined cardiovascular and CNS diseases, including Friedreich ataxia cardiomyopathy, arrhythmogenic and other cardiomyopathies, and APOE4-associated Alzheimer's disease.
Ownership category
akta.pro rank

LEXEO Therapeutics industry classification

Industry
Product category
Genetic medicines / AAV gene therapy biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Gene therapy development
  • AAV vector therapeutics
  • Cardiovascular gene therapy
  • Rare disease treatments
  • CNS gene therapy

Where LEXEO Therapeutics is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

LEXEO Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D

Revenue model

  1. Pre-revenue clinical-stage development: LEXEO is a clinical-stage genetic medicine company with no approved products and no product revenue; future revenue will derive from commercialization of gene therapy candidates for cardiovascular and CNS indications (one-time treatment per patient model, consistent with specialty rare-disease therapeutics).
  2. Strategic equity / collaboration income (capital): Capital raised from strategic partners (e.g., Sarepta Therapeutics strategic investment, Johnson & Johnson research collaboration) and equity financings from institutional investors; not a recurring operating revenue stream.

Go-to-market motion3 records

LEXEO Therapeutics product offering

Product offering

Core offering

LEXEO Therapeutics is a clinical-stage genetic medicine company that develops adeno-associated virus (AAV)-based gene therapies to treat genetically defined cardiovascular and central nervous system diseases. Its pipeline includes lead candidate LX2006 for Friedreich ataxia cardiomyopathy (pivotal SUNRISE-FA 2 trial initiating Q2 2026), plus LX2020 (PKP2-ACM), LX2021 (DSP cardiomyopathy), LX2022 (TNNI3 HCM) in cardiology, and LX1001, LX1020, LX1021 targeting APOE4-associated Alzheimer's disease. All candidates are built on a proprietary AAVrh.10 capsid platform with an optimized Sf9-baculovirus suspension manufacturing process.

Product overview

LEXEO Therapeutics is a clinical-stage genetic medicine company with a portfolio of AAV-based gene therapy candidates organized around two main program pillars: (1) Cardiac programs — LX2006 (Friedreich Ataxia cardiomyopathy, lead asset in Phase 1/2 with SUNRISE-FA 2 pivotal trial initiating), LX2020 (PKP2-ACM, Phase 1/2), LX2021 (DSP cardiomyopathy, preclinical), and LX2022 (TNNI3 HCM, preclinical) — and (2) CNS programs targeting APOE4-associated Alzheimer's disease — LX1001 (Phase 1/2), LX1020, and LX1021. All candidates are built on the company's proprietary AAVrh10 vector delivery platform supported by an Sf9-baculovirus manufacturing process. LEXEO also conducts the CLARITY-FA natural history study (to serve as external control for LX2006) and the HEROIC-PKP2 clinical trial for LX2020. The company retains exclusive worldwide development and commercialization rights to all candidates and pursues both internal development and research collaborations (e.g., Johnson & Johnson for cardiac delivery, BioAgilytix for anti-AAV antibody assay).

Differentiator

Problem solved

Functional benefit

Brands

  • LEXEO: Corporate trade name used interchangeably with Lexeo Therapeutics across investor relations, clinical trials website, and corporate communications.

Products and services

  • LX2006 AAV-based gene therapy candidate (AAVrh.10hFXN) designed to deliver a functional frataxin (FXN) gene to myocardial cells to treat Friedreich ataxia (FA) cardiomyopathy, restoring mitochondrial function and energy production in cardiac myocytes. Lead clinical-stage asset with FDA Breakthrough Therapy, RMAT, Fast Track, Rare Pediatric Disease, and Orphan Drug designations plus EU Orphan Medicinal Product designation.
  • LX2020 AAV-based gene therapy (AAVrh.10hPKP2) designed to intravenously deliver a fully functional PKP2 gene to cardiac muscle for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Granted FDA Orphan Drug and Fast Track designations; evaluated in the HEROIC-PKP2 Phase I/II trial.
  • LX2021 Gene therapy candidate designed to deliver functional connexin 43 (Cx43) protein for a group of inherited cardiac muscle disorders including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. Initially targeting Desmoplakin (DSP) cardiomyopathy.
  • LX2022 Gene therapy candidate designed to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy (HCM) due to mutations in the TNNI3 gene, accounting for approximately 5% of all HCM cases.
  • LX1001 AAV-based gene therapy candidate designed to express the protective APOE2 protein in the CNS of APOE4 homozygous patients to halt or slow the progression of Alzheimer's disease. Granted FDA Fast Track designation; evaluated in the LEAD Phase 1/2 clinical trial.
  • LX1020 Gene therapy candidate designed to express the protective APOE2 protein in the CNS of APOE4 homozygous patients while concurrently delivering miRNA to suppress APOE4 expression, achieving conversion to APOE4/E2 heterozygous profile.
  • LX1021 Gene therapy candidate designed to express the Christchurch-modified APOE2 protein in the CNS of APOE4 homozygous patients; the Christchurch mutation has been observed to protect patients against Alzheimer's disease even in the presence of significant amyloid pathology.

Companies that use LEXEO Therapeutics

Customer profile

Ideal customer profiles2 records

LEXEO Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability10 records

Feature7 records

LEXEO Therapeutics partnerships and signals

Strategic signal

Recent moves7 records

Expansion highlights8 records

LEXEO Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights6 records

Customer concentration

LEXEO Therapeutics social profiles

Digital presence

LEXEO Therapeutics compliance and trust

Trust signal

Compliance5 records

LEXEO Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LEXEO Therapeutics leadership team

Management profile

Number of profiles

Profiles21 records

LEXEO Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

LEXEO Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors32 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LEXEO Therapeutics M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LEXEO Therapeutics

What does LEXEO Therapeutics do?

LEXEO Therapeutics is a clinical-stage genetic medicine company that develops adeno-associated virus (AAV)-based gene therapies to treat genetically defined cardiovascular and central nervous system diseases. Its pipeline includes lead candidate LX2006 for Friedreich ataxia cardiomyopathy (pivotal SUNRISE-FA 2 trial initiating Q2 2026), plus LX2020 (PKP2-ACM), LX2021 (DSP cardiomyopathy), LX2022 (TNNI3 HCM) in cardiology, and LX1001, LX1020, LX1021 targeting APOE4-associated Alzheimer's disease. All candidates are built on a proprietary AAVrh.10 capsid platform with an optimized Sf9-baculovirus suspension manufacturing process.

Is LEXEO Therapeutics a public or private company?

LEXEO Therapeutics is a public company. It is classified as public and is currently operating.

When was LEXEO Therapeutics founded?

LEXEO Therapeutics was founded in 2020. It employs 101 to 250 people.

Where is LEXEO Therapeutics based?

LEXEO Therapeutics is headquartered in New York, United States, in the North America region.

How does LEXEO Therapeutics make money?

Two revenue lines are on record. Pre-revenue clinical-stage development is the primary driver. The others are strategic equity / collaboration income (capital).

Does LEXEO Therapeutics have an API?

No public API is recorded for LEXEO Therapeutics.

What industry is LEXEO Therapeutics in?

LEXEO Therapeutics's product category is Genetic medicines / AAV gene therapy biopharmaceuticals. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAI, Cardiometabolic & Other Systemic Gene Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewLexeo Therapeutics, Inc. Stock 12‑Month Price Target Raised to $25.11, Implies 775% UpsideAnalysts' average price target for Lexeo Therapeutics rose to $25.11 from $20.67, implying about 775% upside from the Nov. 13 closing price. The consensus remains a Buy across nine analysts, with forecasts ranging from $9 to $42 per share.TradingViewLexeo Therapeutics, Inc. Stock 12‑Month Price Target Raised to $24.22, Implies 744% UpsideAnalysts' average price target for Lexeo Therapeutics rose to $24.22 from $20.67, implying about 744% upside from the Nov. 13 closing price. The consensus remains a Buy across nine analysts, with forecasts ranging from $9 to $42 per share.The future of tradingLexeo rises as experimental heart therapy cuts arrhythmia burdenLexeo Therapeutics reported interim data for its gene therapy LX2020, showing an 80% average reduction in non-sustained ventricular tachycardia and a 44% reduction in premature ventricular contractions in 10 patients. The company said the FDA is open to using NSVT as a main goal in a pivotal trial, which it expects to finalize in H1 2027.Investing.comLexeo Nov 2026 presentation: gene therapy shows 80% arrhythmia reductionLexeo Therapeutics presented interim data from its Phase 1/2 HEROIC-PKP2 trial on November 16, 2026, showing an 80% mean reduction in non-sustained ventricular tachycardia and a 44% reduction in premature ventricular contractions in high-dose cohorts. The FDA is receptive to using NSVT as a surrogate endpoint for potential accelerated approval. The company plans to finalize pivotal study design in the first half of 2027.Investing.comWhy is Lexeo Therapeutics stock surging today?Lexeo Therapeutics stock surged 23.7% in pre-open trading after releasing positive interim data from its HEROIC-PKP2 trial of LX2020, showing an 80% mean reduction in non-sustained ventricular tachycardia. The FDA confirmed openness to using NSVT as a primary surrogate endpoint, with a pivotal trial expected in 2027. The company reported a $219.1 million cash position, though Q3 net loss of $38.3 million missed estimates.MarketScreenerLexeo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Lexeo Therapeutics reported a Q3 net loss of $38.3 million and a nine-month net loss of $84.36 million, both higher than the prior year. Basic and diluted loss per share from continuing operations were $0.43 and $0.99, respectively, compared to $0.33 and $1.72 a year ago.TradingViewLexeo Therapeutics Q3 2026 Earnings Call Is LiveLexeo Therapeutics' Q3 2026 earnings call is live, with executives set to discuss financial results and answer analyst questions. The call may include surprise news, as management commentary can move markets.Investing.comLexeo Therapeutics stock gets Stifel buy rating on PKP2 dataStifel reiterated a Buy rating and $17 price target on Lexeo Therapeutics after the company presented PKP2 data showing an 80% improvement in non-sustained ventricular tachycardia. The stock is trading at $2.87, down 71% year-to-date, with a pivotal trial expected in the second half of 2027.Quiver QuantitativeLexeo Reports $38.3 Million Q3 Loss as LX2020 Shows 80% NSVT Reduction | LXEO Stock NewsLexeo Therapeutics reported a Q3 2026 net loss of $38.3 million, or $0.43 per share. The company's LX2020 showed an 80% mean reduction in non-sustained ventricular tachycardia in PKP2 arrhythmogenic cardiomyopathy. The FDA is open to NSVT as a primary surrogate endpoint in a potential accelerated-approval study.The future of tradingLexeo Therapeutics to Report Third-Quarter Financial ResultsLexeo Therapeutics will report its third-quarter 2026 financial results on November 16, 2026. The company will also present a business update covering the HEROIC-PKP2 Phase I/II trial of LX2020 for PKP2 arrhythmogenic cardiomyopathy. A webcast will begin at 8 a.m. ET on that date.